Physician profile
Aaron Miller
NPI 1740892710
$524.68
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $239 · 2021: $286.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $182.48 | 2020-2021 | |
| Pfizer INC. | $73.91 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $52.43 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.27 | 2021 | |
| Novo Nordisk INC | $41.78 | 2020-2021 | |
| Astellas Pharma US INC | $41.09 | 2020-2021 | |
| Amgen INC. | $22.22 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.60 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.34 | 2021 | |
| Antares Pharma, INC. | $14.82 | 2021 | |
| Alfasigma USA, INC. | $12.74 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.